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Preface 
 
This report was commissioned by the R&D Directorate, of the Department of Health, as a 
background document for an international workshop held in November 1999.  The workshop 
was designed to discuss issues related to developing a system for monitoring payback from 
health-related R&D and to provide the Department with advice.  It brought together civil 
servants, NHS managers and R&D directors, members of the research community, 
representatives of the research councils and other major research funding bodies.  It was 
funded by the Department of Health, with sponsorship from the Wellcome Trust.  This 
published report is a slightly amended version of the paper presented at the workshop and 
as such it does not attempt to reflect the very interesting and useful discussions held at the 
workshop.  
 
We gratefully acknowledge help we received in preparing this report, through the comments 
of Jonathan Grant, Barbara Byth, Justin Keen, Tim Packwood, and members of the R&D 
Directorate, Department of Health, and through the efficient secretarial assistance from 
Nicky Dunne and Karen Arnold.  All of the views contained in this document are those of the 
authors alone. 
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EXECUTIVE SUMMARY 
 
Chapter 1 : Introduction 
• The increasing demands for the benefits of payback from publicly funded R&D to be 
assessed are based partly on the need to justify or account for expenditure on R&D, and 
partly on the desire for information to assist resource allocation and the better 
management of R&D funds.  The former consideration is particularly strong in relation to 
the R&D expenditure that comes out of the wider NHS budget. 
• In this report a range of categories of payback will be identified along with a variety of 
methods for assessing them. 
• The aim of the report is to make recommendations as to how the outcomes from health 
research might best be monitored on a regular basis.  The specific context of the report 
is the NHS R&D Programme but many of the issues will be relevant for a wide range of 
funders of health R&D. 
• The introduction sets out not only a plan of the report but also suggests that readers 
familiar with the general arguments and existing literature may choose to jump to 
Chapter 6. 
 
Chapter 2 : Review of Existing Approaches to Assessing the Payback from Research 
• Existing work describes various approaches to valuing research.  Some are ex ante and 
attempt to predict the outcomes of research being considered, others are ex post or 
retrospective. 
• The five categories of benefit or payback from health R&D that have been identified 
involve contributions: to knowledge; to research capacity and future research; to 
improved information for decision making; to the efficiency, efficacy and equity of health 
care services; and to the nation’s economic performance.  These are shown in Table 1 
of the report 
• The process by which R&D generates final outcomes can be modelled as a sequence.  
This includes primary outputs such as publications; secondary outputs in the form of 
policy or administrative decisions; and final outcomes which comprise the health and 
economic benefits.  Feedback loops are also introduced and mitigate the limitations of a 
linear approach. 
• Qualitative and quantitative approaches can be used but there are immense problems 
with time lags and attributing outcomes, and sometimes even outputs, to specific items 
of research funding. 
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• Four common methods of measuring payback can be used.  Expert review, by peers or, 
sometimes, users is the traditional way of assessing the quality of research.  
Bibliometric techniques can involve not only counting publications but also using 
datasets such as the Science Citation Index and Wellcome’s Research Outputs 
Database (ROD).  The various methods of economic analysis of payback are difficult to 
undertake given the costs and problems of acquiring relevant information and 
estimating benefits.  Social science methods include case studies, which can provide 
useful information but are resource intensive, and questionnaires to researchers and 
potential research users. 
 
Chapter 3 : Characteristics of a Routine Monitoring System 
• In moving from ad hoc or research studies of payback towards a more regular 
monitoring it is noted that whereas there has always been a tradition of evaluation of 
research, in the public services in general there is now a greater emphasis on audit and 
performance measurement and indicators.  A review of these various systems suggests 
we should be looking to develop a system of outcomes monitoring that incorporates 
performance indicators (PIs) and measurement rather than an audit system that is 
trying to monitor activities against predetermined targets. 
• Standard characteristics of performance measurement systems do not necessarily 
apply to research where, for example, there are non-standard outputs.  Difficulties have 
arisen in the USA in attempting to apply the Government Performance and Results Act 
to research funding agencies.  It is shown that because the findings of basic research, 
in particular, enter a knowledge pool in which people and ideas interact, it is difficult to 
use a PIs’ approach to track eventual outcomes.  However, for some types of health 
research it has proved more feasible to trace the flow between research outputs and 
outcomes. 
• An outcomes monitoring system could be useful if it met the following criteria: relevant 
to, with as comprehensive coverage as possible of, the funders objectives; relevant to 
the funder’s decision making processes; encourages accurate compliance; minimises 
unintended consequences; and has acceptable costs. 
 
Chapter 4 : Differences Between Research Types 
• The range of differences between types of research can be relevant for the design of a 
routine monitoring system.  The OECD distinguishes between basic research, applied 
research and experimental development.  Most DH/NHS research is applied.  There 
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might be more of a tradition of publication of findings in applied research in health than in 
other fields.  Nevertheless, the publication and incentives patterns operating in basic 
research mean that it would be inappropriate to use bibliometric indicators in a simple 
way across all fields even in health research. 
• Despite having some differences from health research in publication patterns and in the 
detailed categories of payback, the broad approach proposed in Chapter 6 could be 
applied to social care research. 
• Research that is commissioned, especially by the government, has some of the 
minimum conditions built into it that are associated with outcomes being generated, in 
particular because the funder has identified that a contribution in this area will be 
valuable. 
 
Chapter 5 : What Units of Research? 
• The term programme has various meanings including being used to describe a collection 
of projects on a common theme and to describe a block of funding for a research unit. 
• Three main streams or modes of funding can be identified: projects, which are 
administratively grouped into programmes including a responsive programme; 
institutions/centres/units; individual researchers.  These 3 streams are displayed in 
Figure 1.  It is probable that the regular data-gathering for a monitoring system would 
operate at the basic level of each stream or mode. 
• Previous work demonstrates that the full range of benefits can sometimes be applied at 
the level of projects, either in the responsive mode or in programmes, through the use of 
questionnaires to researchers.  Expert and user review and user surveys have also been 
applied. 
• Institutions and centres increasingly have experience not only of traditional periodic 
expert review but also of producing annual reports, although there are debates about 
what dimensions to include in such reviews and reports. 
• Individuals in receipt of research development awards have completed questionnaires 
during and after the awards.  These concentrate on the development of research 
capacity but can go wider. 
 
Chapter 6 : A Possible Comprehensive Outcomes Monitoring System 
• The proposed system is intended for DH/NHS to monitor the outcomes from its R&D in 
order to justify the R&D expenditure and assist with managing the portfolio.  More 
detailed information is required for the latter purpose. 
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• We propose a multidimensional approach be adopted to cover all the dimensions of 
payback and that information be gathered from three sets of sources and Table 3 shows 
which methods would cover which output/outcome categories. 
• Firstly, possibly annually, a questionnaire (possibly electronic) covering most payback 
categories should gather data from the basic level of each funding stream ie. from lead 
researchers of projects, from research institutions/centres, and from individual award 
holders. 
• Secondly, supplementary information should be gathered from external databases 
(including the citation indices and Wellcome’s ROD). 
• Thirdly, a range of approaches ie. user surveys, reviews by experts and peers, case 
studies including economic evaluations, and analysis of sources used in policy 
documents such as NICE guidelines, would be undertaken on a sample basis.  They 
would provide not only supplementary information but, as with the external databases, 
would also verify the data collected directly from researchers. 
• These proposals can be evaluated against the criteria set out in Chapter 3:   
• The system is relevant to DH’s objectives of generating payback in a range of 
categories.   
• Various problems have to be overcome before the system could be  fully decision 
relevant. Firstly it might be necessary to ask researchers to apportion the contribution 
made to specific outputs from various funding streams.  Second, to be decision 
relevant the information would have to be analysed and presented in a manner 
consistent with funders’ decision making processes.  This would involve a) showing 
how for each outcome and output, for example publications, data from one project or 
stream could be compared with those from another and b) demonstrating how 
different outputs and outcomes could be aggregated.   
• The questions of accuracy of data, minimisation of unintended consequences and 
the acceptability of the net costs are also addressed. 
 
Chapter 7 : Research and Monitoring 
• Whilst this report is primarily concerned with moving from ad hoc studies towards a 
routine monitoring system there are issues that need further research. 
• Before embarking on full implementation the feasibility needs to be tested of items such 
as on-line recording of data and asking researchers to attribute proportions of research 
outputs to separate funding agencies. 
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• Once the system is implemented the value of some items can be better assessed, for 
example the additional value provided by self reporting of publications beyond that 
gained from relying on external databases. 
• The data provided by the system would provide opportunities for further payback 
research on, for example, links between publications and other categories of payback.  
• Some items such as network analysis could potentially be added to the monitoring 
system after further examination of them. 
• Finally the benefit from the monitoring system itself should be assessed. 
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CHAPTER 1 : INTRODUCTION 
 
In a number of countries, over the past decade, the evaluation of the returns from public 
sector investment in research and development (R&D) has moved up the policy agenda. The 
desire for evaluation is partly a response to demands for increased accountability to 
taxpayers for public expenditure; partly a result of a desire to improve the information base 
for decisions about allocating research funds; and partly a means of gaining information to 
enable improved management of research. In the US, for example, the 1993 Government 
Performance and Results Act has made evaluation a formal requirement for all government-
supported agencies, including the National Institutes of Health (NIH, 1998).  
 
In the UK, where public funding for health research comes through a number of channels, 
there is increasing pressure for systematic evaluation of health related R&D.  In particular 
changes to the system for allocating the resources within the NHS Research and 
Development Programme budget have meant that attention has to be directed to evaluation 
(Black, 1997). The direct opportunity cost of this substantial investment of NHS funding is 
spending on patient care. NHS research is expected to generate returns, through 
improvements in health and welfare, and thus there is pressure to justify the size of the total 
allocation of resources to research, as opposed to health services. The so-called ‘Culyer 
Reforms’, for example, mean that a portion of the NHS R&D budget is directly contestable, 
requiring that methods be developed for determining the benefits likely to accrue from 
alternative uses of funds and for monitoring their use.  
 
Complementing the policy-related attention, there is a growing body of academic literature 
developing the theory and methodology of research evaluation, and undertaking practical 
studies. One stream of this work has identified a range of benefits, often called 'paybacks' or 
'impacts', from health-related research. These include benefits in the form of contributions to 
knowledge; to increased research capacity; to improved information for decisions; to the 
efficacy, efficiency and equity of health care services; and to economic performance. A 
variety of methods have been used to establish and measure these categories of benefit, 
including analysis of publications, peer review, questionnaires to researchers, case studies, 
and cost-effectiveness analyses. 
 
Most of the work undertaken to date in the UK on payback from health research has itself 
been 'research' rather than 'audit', and it has not addressed the design of systematic, routine 
methods for evaluating benefits from research activities on an ongoing basis. A key issue is 
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how far it is feasible to build on existing work and develop a system suitable for widespread 
implementation.  
  
It is this issue that this report addresses, with the aim of making recommendations as to how 
the outcomes from health research might better be monitored on a regular basis.  It therefore 
refers selectively to existing literature rather than attempting a review of the full range of 
available literature.  Whilst the specific context for these recommendations is the NHS R&D 
Programme, many of the issues and the main elements of the proposals are potentially 
relevant to a range of other funders of health research both in the UK and overseas.  Indeed 
to succeed, some of the proposals may need the tacit or even active support of co-funders 
of research partially supported by the NHS. Moreover, it might be desirable to adopt a co-
ordinated system, to reduce the administrative burden on researchers and minimise the 
scope for strategic behaviour. Thus it is hoped that the ideas presented here will serve not 
only as a basis for discussion within the NHS Programme but also more widely amongst 
other research funding organisations.  
 
The early chapters of the report provide background information about issues relevant to 
measuring the value of R&D. Chapter 2 describes the various dimensions that contribute to 
payback from R&D and outlines alternative ways that payback can be measured. Chapter 3 
describes the characteristics of routine monitoring systems in general, and how these might 
be adapted to suit the context of health related R&D. Chapter 4 discusses the way in which 
differences between the various types of R&D might affect the design of a routine monitoring 
system. Chapter 5 discusses the various streams of research and different levels at which 
research can be monitored. Readers familiar with the general arguments and existing 
literature may choose to omit the earlier chapters. The key proposals are presented in 
Chapter 6, which suggests a system for routinely monitoring R&D funded by the Department 
of Health and NHS. The final chapter, Chapter 7, suggests a number of areas for further 
research, some of which are necessary to check the feasibility of the system sketched in 
Chapter 6, before it can be operationalised. Others are necessary to underpin, test and 
develop the methodology after it has been implemented.  
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CHAPTER 2 : REVIEW OF EXISTING APPROACHES TO ASSESSING THE PAYBACK 
FROM RESEARCH 
 
Introduction 
There is an existing body of work addressing the value of research (OST and PREST, 1993; 
Salter and Martin, 1999).  Some analysis seeks to inform decisions about the level of 
funding that should be allocated to research and how it should be allocated between 
alternative projects, programmes or institutions. Some studies have been described  as ‘ex 
ante’ or ‘prospective’, in other words seeking to predict the outcomes of research which is 
being considered or planned. Other studies have been ‘ex post’ or ‘retrospective’, in other 
words assessing completed research. 
 
Expenditure on research is an investment, expected to generate returns that are sometimes 
called the payback from research. Traditional economic methods for assessing returns on 
investment, based on market prices, are inadequate in the context of research. Research 
conducted in or funded by the public and not for profit sectors, by definition cannot be valued 
simply by its effect on commercial activities or its market price, not least because the outputs 
of publicly funded research may be available freely as a public goods.  
 
Even in the private sector, special tools may be required to analyse returns from this type of 
investment since the relationship between investment in research and its payback may be 
complex and unexpected, and typically occurs over an extended time period. Moreover, the 
returns to individual companies or even industries are likely to underestimate the benefits of 
their research, if commercial benefits spill over between sectors, and if the research 
generates non-commercial benefits. 
 
This chapter outlines the range of different types of payback that might be generated by 
health research. It surveys particular issues that arise when selecting a method to measure 
payback, and outlines methods commonly used to assess payback: review by experts or 
users; bibliometrics; economic appraisal; and social science methods. These methods are 
not mutually exclusive, but rather are presented as a range of alternative approaches.  
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Categories of research payback 
Research produces value, or payback, across a wide spectrum from creating knowledge to 
saving lives to stimulating new industries and to providing employment. Earlier work has 
identified a range of benefits from research (see, for example Gibbons and Georghiou, 1987) 
and specific analysis of health research validated a categorisation of the different 
dimensions of payback (Buxton and Hanney ,1996).  
 
There are five broad categories of payback, summarised in Table 1.  The first category, 
Contribution to Knowledge, is valuable both insofar as the production of knowledge is an end 
in itself, and if the knowledge is likely to contribute in the future to the production of other 
types of payback.  
 
The second category comprises benefits to research processes and the organisations 
conducting research. These paybacks accrue if research refines research methods and 
competencies, either technical or methodological. They may also accrue if the results of one 
research project refine the parameters for future research, and if the skills, networks and 
knowledge acquired by researchers increase as they conduct research. Furthermore, there 
is some evidence that organisations engaged in research are more likely to use outside 
research findings and exploit the results of scientific breakthroughs (Gambardella, 1992). 
Some commentators believe that being involved in research is an important part of staff 
development and may increase the ability of NHS staff to adapt their practice in line with 
research findings (Elderidge and South, 1998).   
 
The third category of payback constitute political and administrative benefits. There may be 
benefits if research contributes to an improved information base for decisions which can 
range from those taken by national policy makers to those from local administrators and 
royal colleges. There are sometimes other benefits to politicians, public servants and other 
decision-makers. These include commissioning research in order to be seen to be ‘doing 
something’; in order to delay decisions; or to legitimate decisions actually taken for other 
reasons.  
 
The fourth type of payback involves health gains.  Research may bring direct returns if it 
reduces the cost of providing health care, allowing health gain by releasing resources that 
can be used to better effect elsewhere. Research which leads to intellectual 
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Table 1  Categories of Research Payback 
Payback category 
a. Contribution to knowledge  
b. Benefits to future research: 
i. future research can be more precisely defined and targeted, in either method 
or scope; 
ii. increase the skills, knowledge and professional networks of researchers; 
iii. enhanced ability to utilise or capture existing research. 
iv. staff development/educational benefits 
c. Political and administrative benefits: 
i. improved information base for decision-making, which is assumed to be 
beneficial even if particular research findings are not ultimately implemented; 
ii. benefits to decision-makers including being seen to take action, delay 
decisions, or justify decisions taken for other reasons. 
d. Health benefits: 
i. reduction in the cost of delivering services; 
ii. improvements in the quality of service delivery, including increased patient 
and staff satisfaction; 
iii. improved  efficacy of health services, leading to increased health gain; 
iv. improved equity, by improved allocation of resources across areas, better 
targeting and improved accessibility of services. 
v. revenues to NHS from Intellectual Property Rights 
e. Broader economic benefits: 
i. commercial exploitation of innovations; 
ii. productivity gains resulting from a healthier workforce. 
 
Source: Buxton and Hanney 1997. 
 
 
property may generate income for the NHS, although it should be noted that this constitutes 
a transfer rather than an absolute gain. Research may also bring qualitative improvements to 
the process of health care delivery, such as reductions in waiting times, in turn improving 
patient satisfaction with services and/or staff satisfaction. Research may improve the 
effectiveness and efficacy of health care, thus resulting in a health gain. It is also feasible 
that some types of research might improve equity of access to health services, by improving 
the ability to allocate financial resources, by allowing improved access to health services, 
and by addressing problems particularly relevant to the least well-off in society.  
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The fifth type of payback comprises economic benefits accruing outside the health sector. 
R&D which leads to the development of new products or processes may have a direct 
impact on economic growth and on employment. Non-commercial health-related research 
may also have an indirect impact on economic indicators, if it improves productivity by, for 
example, reducing sickness-related absenteeism.  
 
General issues in the measurement of payback 
A number of issues must be considered when selecting a measure of any or all of these 
dimensions of payback. Three are discussed briefly in this section. Later chapters provide 
detailed discussion of how these issues are manifest when measuring Department of Health 
R&D.  
 
Measurement of outputs versus outcomes and the development of a payback model  
Traditionally a distinction has been made between output indicators which measure the 
direct products of research, and outcome indicators which measure changes in variables 
directly related to health and economic benefits. Examples of output indicators include the 
number of papers published and disseminated at conferences, and the number of completed 
PhDs. Outcomes such as health benefits are usually harder to measure directly.  Therefore, 
output indicators might usefully be used as accessible indicators of outcomes if there is 
evidence of correlation between the two.  
 
It can be helpful to model the process whereby R&D generates final outcomes. Buxton and 
Hanney (1996, 1997) use a sequential model, starting with the identification of R&D needs.  
There is then the first of two interfaces between the political and professional environment 
and the research processes.  The permeability of the interfaces can be important if 
outcomes are to be achieved and the first interface involves the commissioning and 
specification of research to meet the identified need.  The primary, or initial, outputs emerge 
from the subsequent research processes and include publications.  There is then the 
second, or dissemination, interface when findings are relayed to the political or professional 
environment. This is followed by a stage which may include the generation of secondary 
outputs in the form of policy or administrative decisions, manifest in, for example, national 
ministerial decisions or local guidelines. Final outcomes often result from the application of 
these secondary outputs, and comprise health and economic benefits. Although in its 
simplist form this is a linear model, it can incorporate and highlight the variety of feedbacks 
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that occur, and can be contextualised within a model recognising the existence of a 
‘knowledge pool’. 
 
Quantitative versus qualitative assessment methods 
Indicators of both the output and outcomes of research may be quantitative or qualitative. 
Contribution to knowledge may, for example, be measured quantitatively by the number of 
papers published, or qualitatively by expert review.  
 
The choice of qualitative or quantitative method depends on the available indicators and on 
whether relevant dimensions can be captured by available quantitative indicators. In 
practice, qualitative methods are often more costly to implement, and may generate results 
that are less comparable across different projects or institutions. The lack of comparability 
may, however, result from inherent differences between projects, differences that would be 
masked by a quantitative indicator.  
 
Attribution, time lags and the 'contributive role' 
It is often not straightforward to attribute a given outcome or even output to its component 
research-inputs or, conversely, to track the outcomes and outputs of a given piece of 
research. Isolating the payback from one research project, or even one research institute, is 
difficult since research is often a collaborative, cumulative process. Any one breakthrough in, 
for example, medical practice, is likely to draw on many different research projects. 
Conversely, one research project may have multiple impacts. The key question is: would a 
particular payback have been achieved without a particular piece of R&D?  
 
Attribution is also complicated by the considerable time that may pass before a research 
project bears fruit. The now classic study, Project Hindsight, which examined the relationship 
between scientific research and innovations in defence, found that up to 20 years may 
elapse between the publication of research results and realisation of applications (Sherwin 
and Isenson, 1966). 
 
The time lags mean that full assessment of payback will take place either after considerable 
time has elapsed or under conditions of uncertainty about the eventual level of impact. In 
other words, interim assessment of payback will have to be based on the likelihood (or 
probability) of particular outputs and outcomes.  
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Methods of measuring payback 
The issues outlined above arise regardless of the method used to measure payback. A 
number of methods are currently employed, in various contexts. Four of the most commonly 
used types of method are described briefly in this section. Table 2 summarises the methods, 
and their advantages and disadvantages.  
 
Expert review, by peers or users 
Expert review may be used to judge the value of individual publications, or of whole research 
programmes.  Peer review is a traditional means by which the value (especially in terms of 
scientific quality) of research is assessed. It is undertaken by one or several experts in a 
field, able to judge the contribution to knowledge made by particular research or research 
groups. It provides a means whereby expert technical judgement can be employed. This is 
particularly useful when outcomes are intangible or multidimensional, or when judgement is 
required to identify the particular contribution made by one research project to a complex 
outcome.  
 
Review may also be undertaken by the users of research, defined as those who might, by 
virtue of their own responsibilities and interests, be expected to use the results of the 
research. They may include health care policy makers, health care professionals, industrial 
representatives, and members of patient groups. A variety of different techniques may be 
used to gain the views of users, including panel discussions, interviews, and questionnaires.  
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Table 2 : Characteristics of different approaches to assessing payback* 
Source of information Research type Strengths Weaknesses Relative cost 
Review - expert/technical All types • can provide information on a range 
of dimensions of value and of the 
role of different researchers and 
organisations. 
 
• may be a burden on reviewers; 
• may be biased, because relies on information from a small 
number of individuals; 
• only qualitative information or, if use scoring methods, these may 
be hard to validate and not transferable. 
low total cost, high cost to 
individual reviewers. 
Review - by users Applied and 
developmental 
• can provide comprehensive 
information about a range of valued 
dimensions; 
• if use surveys, overcome the small 
numbers problem. 
• considerable information may have to be given to reviewers; 
• qualitative information or non-transferrable scoring system; 
• may be hard to develop and analyse survey - results may be 
ambiguous; 
• users may be unable to attribute results to projects or 
programmes.  
medium (development  and 
analysis of surveys may be 
difficult). 
Questionnaires to 
researchers 
All • can provide comprehensive 
information about value. 
• may have low compliance, since places an administrative burden 
on researchers; 
• responses may not be accurate, may need verification; 
• researchers may not have full information about all uses of and 
outcomes from their research.  
Medium, depending on 
level of  validation required 
(does impose costs on 
researchers).  
Bibliometrics 
(publications) 
Basic, applied 
(some) 
• information is readily accessible; 
 
• only a partial indicator of payback; 
• may be biased by confounding effects of differences between 
subject areas and types of research. 
medium-high (depending 
on type of analysis 
conducted). 
Economic assessment Applied and 
developmental 
• structured and comprehensive 
framework. 
• considerable data requirements; 
• results dependent on assumptions, especially given the level of 
uncertainty and extended period over which benefits accrue; 
• many benefits not able to be quantified. If use cost-effectiveness 
analysis, can’t compare across programmes; 
• only feasible to apply to a subset of R&D projects.  
high (data collection and 
analysis) 
Case studies All • provides information about 
causality, and about the 
relationship between R&D and its 
impacts; 
• provides comprehensive 
information about all dimensions of 
payback. 
• results may not be generalisable; 
• hard to compare across different case studies. 
Medium (vary with number 
of case studies). 
* Based on Williams and Rank, 1998. 

11 
A number of different methods can been employed in the review process. It may involve 
examination of publications, site visits, and interviews. The process may be informal or 
structured. If it is structured, reviewers may be requested to give particular qualitative 
information or to make quantified ratings (Cozzens, 1997). 
 
Bibliometric techniques 
Bibliometric analysis uses data about publications or patents to analyse the payback from 
research. Bibliometric analysis of payback commonly comprises comparison of groups of 
researchers in terms of their activity, measured by the number of publications and type of 
journal in which publications appear; and their impact, measured by the number or type of 
citations. (Narin, Olvastro and Stevens, 1994).  An early, classic study measuring the linkage 
between articles and citations, assessed the influence of basic scientific research on medical 
breakthroughs by tracing citations. (Comroe and Dripps, 1974, 1976).  
 
There are a number of public datasets suitable for bibliometric analysis, including the 
Science Citation Index (SCI), the Social Science Citation Index (SSCI), Medline and so on. 
These datasets comprise information about all papers appearing in a very large number of 
journals over a period of years. The information held in the datasets includes information 
about the authors (including their addresses); keywords; information about the journal; and 
information about the number of citations of each paper and where they appear. The 
Wellcome Policy Unit has a database, the Research Outputs Database (ROD), which 
includes all of the information contained in the SCI, as well as information about funders 
where this is included in the publication. (Lewison, 1998).  
 
Analysis sometimes uses a Journal Impact Factor (JIF), which is a score calculated for each 
journal, based on the total number of citations of all papers appearing in that journal during a 
particular period, weighted by the number of articles it publishes. By this measure papers 
published in journals with high JIFs (for example, Science and Nature)  are deemed to be 
more valued than papers in less frequently cited journals. 
 
Bibliometric analysis using published datasets has the advantage of imposing few direct 
costs on researchers. It can therefore be applied across a large number of groups of 
researchers to compare the output of, for example, all of the hospitals in the UK. If used 
routinely it may create a particular incentive structure. The use of JIFs, for example, rewards 
research with a greater likelihood of being published in journals with a high JIF. This may be 
a desirable or an undesirable consequence, depending on the objectives of decision 
makers.  
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There are also a number of disadvantages to bibliometric analysis (Adams, 1997; Herbertz, 
1995). There are practical difficulties in using the databases: they are not 100% accurate or 
complete; and they cover only a subset of journals, with relatively poor coverage of, for 
example, health services research journals (Black and Davies, 1999) and journals that are 
not published in English. The normal number of citations and publications varies between 
subject areas, meaning that direct comparisons can be made only after controlling for 
differences. Moreover, publications are only one output of research, and they are an output 
not useful in themselves but useful only insofar as they indicate a contribution to knowledge, 
improvement in research capacity, or expansion in the information base available to 
decision-makers.  
  
Economic assessment 
This section provides a very brief survey of a number of the different methods of economic 
analysis that can be used to measure a number of the dimensions of payback from research.  
 
Econometric studies use multi-variate statistical methods to estimate the contribution of 
research expenditure to economic growth (at a national level) or profit (at the level of 
individual industries or companies). In these studies, the value of research is taken to be its 
contribution to economic growth, productivity or profit. 
 
Various investment appraisal techniques measure the rate of return on research as an 
investment, by comparing a quantitative measure of benefit against cost. For example, one 
study of the return to private sector research found an average internal rate of return of 28% 
(Mansfield, 1991). As with economic evaluation, these techniques usually discount costs and 
benefits which, given the extended period before benefits accrue, leads to results with 
apparently low returns. 
 
Portfolio analysis combines a number of different projects by using programming techniques 
to find an optimal allocation of resources between the projects. By allowing a number of risky 
projects to be combined, portfolio analysis provides a means of managing uncertainty.  
 
Option appraisal treats investment in research as the purchase of an ‘option’, opening future 
possibilities. In other words, developing an R&D capacity gives the developer the option of 
future involvement in particular areas. 
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Economic evaluation allows systematic comparison of costs and benefits. Benefits may be 
measured by a particular health gain, such as a change in life expectancy, by QALYs, or by 
monetary impact. Weisbrod, for example,  conducted retrospective analysis of the value 
generated by the research leading to the successful development of a vaccine for polio in 
1957. He estimated that by 1971 the total monetary value of the treatment costs saved and 
the reduction in mortality and morbidity was $US 1,350 per case prevented (1957 prices), 
equivalent to a return on research investment of 11-12% (Weisbrod, 1971).  In practice, 
economic evaluation is difficult to undertake, given the cost and problems of acquiring 
relevant information and estimating benefits.  
 
Social science methods 
A number of methods are used by social scientists to estimate payback, including case 
studies and questionnaires.  
 
Case studies can be defined as ‘the systematic documentation of the impacts of R&D that 
has been carried out in the past’ (Williams and Rank,1998, p53). Case studies may be 
undertaken as an end in themselves, or may be undertaken to provide information to be 
used as an input to economic appraisal. They have the advantage of being able to provide 
information on a range of different dimensions of payback, potentially on all of the 
dimensions outlined above including the impact of R&D on policy, and can be used to 
establish causality. Case studies are, however, resource intensive and so are unlikely to be 
appropriate as the main method in a routine monitoring system (Buxton et al, 1999).  
 
Questionnaires are commonly used to gather information on ‘payback’ from the researchers 
themselves, and even where formal questionnaires have not been used, many funders have 
adopted some system of structured final reports which may act, rather like a questionnaire, 
as a source of information on initial publications. Considerable effort may be required to 
validate the instrument and to analyse results.  
 
Nonetheless questionnaires are still likely to be less resource intensive than case studies, 
making them more suitable for routine monitoring. Response rate may be poor if it is 
voluntary, given the cost in researcher time required to fill in questionnaires. If researchers 
think there is a link between their answer and their funding, response rates may be higher, 
but there may then be a danger of bias.  
 
Questionnaires can also be used to gather information from users of research and can be 
administered to a large number of people routinely.  The Economic and Social Research 
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Council (ESRC) is undertaking a major study of the use of user panels and network analysis, 
to assess the impact of research on non-academic users.  Exploratory work showed that 
users are likely to have difficulty in attributing research findings to particular bodies or 
projects, suggesting that users may not be able to assess all types of R&D (Cave and 
Hanney, 1996; ESRC, 1997).  
 
Conclusions 
The choice of a method for measuring payback depends, ultimately, on the objectives of the 
evaluator, since different methods highlight different dimensions of payback. Clear 
understanding of policy objectives, in the context of which categories of payback are most 
important, must therefore inform the selection of a method. For example, a funder concerned 
primarily with increasing research capacity and facilitating health gains should not rely solely 
on bibliometric methods to measure value. As will be discussed in subsequent chapters, the 
dimensions of value important to the Department of Health can be measured adequately 
only if a multiple measures are used. This principle underlies the system we sketch in 
Chapter 6.  
 
This chapter has focused on research leading to the development of methods for valuing 
payback. A routine monitoring system needs to reflect this research experience, but if it is to 
be routinely used it must also address particular operational questions, which are discussed 
in Chapter 3.  
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CHAPTER 3 : CHARACTERISTICS OF A ROUTINE MONITORING SYSTEM 
 
Introduction 
Chapter 2 illustrated the range of approaches that have been adopted in ad hoc research 
studies of payback. As we move examine the possibilities of moving towards a system that 
might routinely monitor the payback from a funding agency's health research, we need to 
focus on three dimensions. the thinking needs to push forward in a number of directions. 
Firstly, weit needs to move towards an approach that can be routinely undertaken routinely.  
Secondly, weit needs to accommodate focus on outcomes as well as outputsand outcomes. 
Thirdly, it we needs to find measures which can encompass the full list of payback 
categories.  
 
In considering thewhat are appropriate characteristics of a monitoring system it is useful to 
begin by examininge the wide range of assessment approaches that are applied to public 
services in general. A range of bodies have been active in this field, for example, in the UK, 
the Audit Commission, the National Audit Office (NAO), and the Treasury and infrom the 
USA, the Office of Management and Budget.  Some previous and ongoing attempts to apply 
monitoring systems to research also offer useful insightslessons, particularly into the 
problem of attribution when analysing basic research. Overall, the chapter explores the 
general criteria and necessary characteristics offor a monitoring system.  
 
Assessment approaches and characteristics of systems 
Peer review has long been an integral part of the process of assessing research proposals 
and products. However, thethis tradition of evaluatingion of research now has to be put into 
the context of a general growth of interest in output and performance measurement in the 
public sector in the UK (see, for example Cave et al, 1990)and elsewhere (see, for example, 
Cave et al, 1990; Treasury Select Committee, 1999).  This expansion of performance 
measurement and indicators is just one facet of a general development in many Western 
democracies of what has been referred to as ‘New Public Management’ (see, for example 
Pollitt, 1993).  It has resulted in a situation where there is now a wide range of overlapping 
approaches to assessment in the public services which include: evaluation; audit; output and 
performance measurement; and performance indicators (PIs).  One example of overlap is 
that (PIsperformance indicators can be incorporated into, or used by, any of the other 
approaches.)  Furthermore, there are debates about how far traditional programme 
evaluations are converging with performance measurement or audit (see, for example, Keen 
(forthcoming); Wisler, 1996, and, specifically in relation to research, Cozzens, 1997).  
 
  16
The term ‘evaluation’ covers a wide range of activities but generally it involves making 
subjective judgements based on data to varying degrees on data.  In relation to research, 
evaluation it is often based on peer review, and whilst such evaluations are sometimes 
routine, they rarely examine outcomes. The term ‘audit’ also covers various activities 
including financial audits, which concentrate on issues such as probity, and the NAO's Value 
for Money audits, where it is sometimes claimed that the three3 E’s of economy, efficiency 
and effectiveness are important (though Keen, forthcoming, disputes this).  Such audits can 
involve checking that planned activities have been completed.  ‘Medical audit’ is different 
again: in an exchange in the Public Accounts Committee Alan Langlands agreed that the 
term medical or clinical audit involved either self-assessment or peer review as opposed to 
the third party activity normally associated with audits (HC 304, 1995-6).   
 
The Value for Money reports from the NAO or the Audit Commission generally involve the 
production of many blocks of information or PIs, upon which judgements are made.  The 
Audit Commission conducts follow-up studies which track progress using indicators based 
on the original study recommendations.  A recent example involved the Accident and 
Emergency Services (Audit Commission, 1998), where independent judgements from the 
auditors, such as 'there is still scope for better deployment of staff' (p1), are made on the 
basis of the indicators.   
 
As a result of government pressure there was a large increase in the number of output and 
performance measures listed by departments in the Public Expenditure White Papers - rising 
from 500 in 1985 to about 2,300 in 1990 (Treasury, 1990).  Further work by central 
government on these issues throughout the 1990s has seen several strands of thinking 
including the use of performance targets.  The development of resource accounting has led 
to the situation where in 1999-2000 UK government departments produce ‘their first set of 
Output and Performance Analyses’ (McConaghy, 1999, p62).  There has also been the 
development of Public Service Agreements (PSAs) which include a series of performance 
targets for each department which are 'wherever possible, "SMART" - specific, measurable, 
achievable, relevant and timed' (Chief Secretary to the Treasury, 1998, p5).  The Treasury 
Select Committee reported an estimate 'that two thirds of the PSA indicators were of 
outcomes' (Treasury Select Committee, 1999, para 14).  It also reported a Treasury 
assessment that there were about 600 PSA targets but about 1000 Output and Performance 
Analyses targets.  The committee argued that although the two had a separate history it 
would be worthwhile amalgamating 'the two documents on the next occasion on which a full 
set of PSAs is published' (para 22). 
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It is certainly desirable to monitor a system against its objectives. However, as discussed 
below, it is unlikely that a monitoring or an audit system for research output and outcomes 
will be able to be assessed against precisely defined quantifiable targets. 
 
It might be reasonable to conclude from this section that, at this stage in our understanding 
of payback from research, we should be looking to develop a system of outcomes monitoring 
that incorporates performance indicators and measurement, rather than an audit system that 
is trying tothat could monitor activities against predetermined quantitative targets. 
 
General characteristics of performance measurement systems and their relevance to 
research 
In the development of performance and output measurement systems there are various 
indications that research is regarded as a rather separate area of public expenditure.  When 
describing the use of output and performance measures in government departments Lewis 
and Jones (1990) recognised that different types of PIs were appropriate for the different 
types of activity performed in government departments. But in listing specific PIs for R&D 
establishments they noted that these PIs were ‘mostly directed towards measuring the 
performance of R&D administration' (p51). The difficulty of including research outputs in 
performance audits or measurement systems was again highlighted by the NAO report into 
performance review in the Defence Evaluation and Research Agency.  It noted that Treasury 
guidance to agencies recommended targets on financial performance, volume of output, 
quality of service and efficiency.  The NAO report continues, however, without demurring, 
'The guidance singles out research establishments as being examples of agencies with non-
standard outputs: it makes little sense to count the numbers of reports issued where a 
'report' is not of constant size, cost or value' (NAO, 1997, p71).  The NAO report, 
nevertheless, did undertake some analysis to show the annual production of scientific 
papers per research leader. They also examined the Agency's customer satisfaction surveys 
and undertook some customer focus groups of their own.   
 
A review of research evaluation in the UK noted that research is funded by different 
government departments for differing purposes and, therefore, claimed that different types of 
evaluation would be appropriate.  Of the Department of Health's research it noted that 'this 
relatively complex system militates against a uniform approach to evaluation' (Hills and Dale, 
1995, p40).  
 
Difficulties in dealing with research in a general performance monitoring system have 
occurred in the USA where the 1993 Government Performance and Results Act (GPRA) 
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required federal agencies to set strategic goals and to use performance measures for 
management and budgeting.  The Committee on Science Engineering and Public Policy 
(COSEPUP) recently reported that 'the specific goal of GPRA is to focus agency and 
oversight attention on the outcomes of government activities .... [but] .... Development of 
plans to implement the act has been particularly difficult for agencies responsible for 
research activities supported by the federal government because of the difficulty of linking 
results with annual investments in research' (COSEPUP, 1999).  According to Cozzens 
(1997) many research agencies hoped that they would be exempt from the GPRA, but in fact 
this is not going to be the case.  Nevertheless she explains why 'research outcome 
measures are not, and in fact will not, become available for GPRA-type performance 
reporting' (1997, p78). 
 
Following an analysis of the differences between traditional evaluation of a research 
programme and the requirements of the GPRA, Cozzens (1997) lists various indicators that 
would 'satisfy the standard GPRA template' (p86).  They are: publication counts; citations 
per publication; doctorates produced; and user involvement and satisfaction ratings.  She 
then comments that, 'The problem with the set, of course, is that it leaves out virtually all of 
what researchers themselves find important about their work' (p86).  As a way out of the 
difficulties she suggests that: 'many agencies are now turning to the alternative goal-setting 
and reporting format available under GPRA.  This alternative format allows descriptive 
performance goals, requiring only that agencies paint a word picture of the difference 
between minimally effective and successful performance.  The match between actual 
performance and the word picture is subject to the same requirements for evidence that 
apply to quantitative goals.  This path thus provides both the flexibility research agencies 
need to maintain a focus on outcome rather than outputs of their process, and the rigorous 
standards GPRA encourages' (p88). 
 
This discussion highlights the difficulties in trying to develop a set of research output and 
outcome indicators that fit into standard approaches to output and performance 
measurement.  This suggests that a highly specific monitoring system might have to be 
developed for the outcomes of health research.  Furthermore, it is likely that such a system 
might be relevant for only some types of research. Cozzens' analysis seeks to show the 
advantages in the research context of traditional programme evaluation or assessment over 
summary PIs.  She describes how research outputs enter a knowledge pool (Gibbons and 
Johnston, 1974) in which ideas and people interact and produce innovation through 
unpredictable paths which makes the tracking of eventual outcomes particularly difficult to 
do other than through expensive retrospective studies. The analysis of Buxton and Hanney 
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(1997) and Hanney et al (forthcoming) acknowledges the complexities caused by the stock 
or pool of knowledge but also describes more readily identifiable flows of knowledge that can 
sometimes occur, especially with policy research or technology assessment.  
 
For basic research programmes, COSEPUP arguesd that it is necessary to evaluate 
programmes 'by using measures not of practical outcomes but of performance, such as the 
generation of new knowledge, the quality of research, the attainment of leadership in the 
field, and the development of human resources'.  These could best be evaluated, it 
recommends, by expert review and by using the alternative descriptive GPRA format 
outlined above.  Both the National Science Foundation (NSF), and the National Institutes of 
Health (NIH), however, make a distinction between outcome performance, to which the 
above analysis applies, and processes or means where more quantitative approaches 
against targets are recommended.  The NIH has been allowed to have its performance 
assessed at a higher level of aggregation than the NSF. 
 
For applied research COSEPUP suggests that the requirements of the GPRA could be met 
by annually measuring progress towards practical outcomes.  It recommends setting 
outcome targets in the form of milestones. For example, a programme might be set the 
milestone of adapting fibre-optic laser surgery for the treatment of prostatic cancer, or of 
devising a prototype DNA sequencing machine (COSEPUP, 1999).  There are, however, 
likely to be significant problems when trying to set appropriate milestones for health R&D 
programmes.  Although much DH/NHS R&D is applied, it is unlikely to be the case that 
precise, verifiable outcomes can be specified for programmes which cover a wide range of 
topics. In practice, it is easier to set milestones that relate to process rather than to outcome 
variables.  
 
Some commentators argue that it is impossible to measure the value of R&D. There is, 
however, convincing evidence that it is feasible to measure value, for at least some types of 
health-related R&D (Buxton and Hanney, 1997). It is not, however, clear that the same 
indicators can be used to measure the value generated by all types of R&D. As will be 
discussed in Chapter 4, it may not be possible to use the same set of indicators to measure 
the value of basic bio-medical science, health services research and social care research. 
This means that, in the context of DH funded R&D, a comprehensive routine monitoring 
system must comprise a variety of different indicators and assessment techniques. A system 
of this type might be called an Outcomes Monitoring System. As will be discussed in Chapter 
6, which outlines the features of such a system, combining different indicators presents 
substantive analytic problems. Not combining them would, however, sacrifice 
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comprehensiveness for tractability. The next and final section of this chapter describes the 
criteria against which a routine monitoring system must be judged. 
 
Criteria for a routine monitoring system for R&D 
Various criteria have been developed for judging the adequacy of individual performance 
indicators for higher education (Cave et al, 1997; Sizer, 1979). These criteria can be 
adapted so they are suitable for judging an outcomes monitoring system for health-related 
R&D. A system will provide information useful for managing R&D if it meets the following 
criteria: 
 
∗ relevance to objectives, in that it measures the full range of dimensions relevant to 
the funders’ objectives.  It should be as comprehensive as possible; 
 
∗ decision-relevance, in the sense that the information can be analysed and 
presented in a way that is consistent with the funders’ decision making processes; 
 
∗ truthful compliance, in that the system should encourage those holding 
information to comply with requests to reveal the information at all, and to reveal it 
accurately. This can be achieved either by giving appropriate incentives to those 
holding information, or by monitoring their returns to check their completeness and 
accuracy; 
 
∗ minimises unintended consequences, in other words has incentives rewarding 
desirable behaviour. The previous criterion, truthful compliance, refers to 
behaviour related to giving information. This criterion refers to behaviour related to 
the R&D activities themselves; 
∗ acceptable costs relative to its benefits.   
 
The routine evaluation of research in universities in the UK conducted through the Research 
Assessment Exercise (RAE) powerfully illustrates the importance of considering incentives. 
Although the RAE assessment process has evolved over time (see, for example, Cave et al, 
1997) in every case it has involved peer review of departments informed by review of 
publications and data on research students and on income.  Its importance in terms of 
research resources to departments is so great that it intensifies the pressure on academics 
to give maximum attention to the quality of their research as measured by RAE, and as a 
result to be less concerned with other research outcomes resulting from the research 
findings. It is therefore important that any system for evaluating NHS research should 
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recognise its interactions with the RAE.  Secondly, the specific indicators used in the RAE 
provide a good example in the discussion below of how incentives can operate.NHS and 
university R&D are not always distinct. 60% of NHS publications involve a collaboration with 
at least one university author.  
 
The specific indicators used in the RAE provide a good example of the operation of  
incentives. Performance indicators form a vital part of the incentive structure, insofar as they 
connect behaviour with rewards or penalties.  Incentives operate by rewarding or punishing 
particular courses of action. They may be financial or non-financial, since people have 
objectives relating to both of these types of reward (or penalty). Non-financial incentives may 
relate to private self interest, for example, a desire for leisure time or peer approval. They 
may also related to public interest, for example the desire of public officials and medical 
professionals to fulfil their agency role to patients or citizens (Scott, 1997; Wilson, 1989).  
 
Performance measures may be designed to be part of incentive systems and have intended 
consequences, such as the payments to GPs for health promotion activities, designed to 
stimulate increased activity. They may also have unintended consequences. In the context 
of R&D, incentives similarly reward particular behaviour, in both intended and unintended 
ways. For example, for the 1992 HEFCs’ Research Assessment Exercise the impression 
was gained by researchers that the number of publications would be used as a performance 
indicator. This led to publication inflation (O'Brien, 1994).  
 
More generally, unintended consequences may result from using PIs which only measure 
the easily measurable dimensions of research outcomes. Focusing on these 
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measurable dimensions gives individuals an incentive to focus on activity affecting these 
dimensions, which may mean that they ignore other, equally important dimensions. More 
generally the fact that only a subset of the dimensions that are important can be observed 
and easily measured means that it may not be optimal to use as performance indicators 
those that could be applied.  To do so might lead to undesirable behaviour, as individuals 
respond to the indicators, ignore other dimensions that are as important.  
 
Conclusions  
The issues outlined in the first parts of this chapter mean that the value of health-related 
R&D cannot be measured adequately using a conventional set of PIs. As will be discussed 
further in Chapter 4, a system based on a single set of conventional PIs is unlikely to be able 
to accommodate all types of R&D, from basic biomedical science to health services 
research. Conventional performance indicators are not, therefore, sufficiently comprehensive 
to capture key dimensions valued by funders such as the DH. A more complex monitoring 
system will be necessary. 
 
Appropriate approaches therefore need to be developed for application to health R&D. 
Chapter 6 sketches an outline of an outcomes monitoring system that potentially meets the 
criteria outlined in the latter part of this chapter: relevance to funders’ objectives; decision-
relevant; accurate; minimises unintended consequences; and with acceptable net costs. 
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CHAPTER 4 : DIFFERENCES BETWEEN RESEARCH TYPES 
 
Research and development activities may be categorised in a number of different ways. 
Differences occur on a variety of dimensions: sources of finance; types of knowledge 
generated; norms of information disclosure; reward systems (Dasgupta and David, 1994).  
Recognising the differences is important to the design of the routine monitoring system 
sketched in Chapter 6, since different types of research may perform differently on any 
particular indicator.  This chapter discusses first, differences between basic, applied and 
experimental R&D; second, the special case of social care research; and third, differences 
between commissioned and responsive research.  
 
'Basic' versus 'applied' research 
The OECD distinguishes three types of R&D activity (OECD, 1994): 
 
• basic research is defined as ‘experimental or theoretical work undertaken primarily to 
acquire new knowledge of the underlying foundations of phenomena and observable 
facts, without any particular application or use in view’; 
 
• applied research is defined as ‘original investigation undertaken in order to acquire new 
knowledge. It is, however, directed primarily towards a specific practical aim or objective’; 
 
• experimental development is defined as ‘systematic work, drawing on existing knowledge 
gained from research and practical experience, that is directed to producing new 
materials, products and devices; to installing new processes, systems and services; or to 
improving substantially those already produced or installed’.  
 
In the context of health-related research, for example, basic research includes mapping the 
Genome; applied research includes relating particular clinical symptoms to particular genetic 
patterns; and experimental development includes developing a routine test or a treatment for 
the clinical symptoms. 
 
Using the OECD's definitions, the Office of Science and Technology (OST) estimate that in 
the UK in 1996/7, basic research accounted for 32.1% of total government R&D expenditure; 
applied research 40.6% and experimental development 27.3% (OST, 1998). In the same 
year, basic research accounted for 17% of DH R&D expenditure; 63% of the MRC's 
expenditure; and none of the NHS's R&D expenditure.  An alternative estimate of the 
balance between applied and basic R&D can be made by examining the type of journal in 
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which publications funded by public organisations appear. Work currently underway at the 
Wellcome Trust Policy Unit suggests that in 1996 at least 54% of NHS-funded work was 
published in applied journals and at least 32% in basic science journals (Personal 
communication, M.Yare and J.Grant). These estimates suggest that both are important in 
the DH and NHS, and that both need to be accommodated in any comprehensive routine 
monitoring system.  
 
Basic, applied and experimental R&D may vary in any or all of the dimensions listed above. 
Basic science and some types of applied research are more likely to be characterised by 
knowledge outputs that are placed in the public domain (Dasgupta and David, 1994). 
Experimental development is, by contrast, sometimes intended to develop tradable products 
or applications in which case it is patented or kept secret.   
 
Although they differ in important respects, different types of R&D are complementary parts of 
one process. Basic research can be shown to play a vital role in, for example, breakthroughs 
in medical treatment and diagnosis (Comroe and Dripps, 1974, 1976). And conversely, the 
questions faced in experimental and applied work can usefully inform basic research.  
 
The process of information flow between different types of R&D is complicated by and 
sometimes impeded by their differences, particularly differences between their goals, norms 
and reward systems, and by barriers between organisations. Current government policy 
therefore seeks to facilitate collaboration, increasing the rate at which the results of basic 
research inform applications and facilitating the process by which basic research is informed 
by applied questions. This is evident both in policy relating to the delivery of health care and 
in research policy. In the context of research policy, collaboration is encouraged between 
basic scientists and those able to develop the results (Our Competitive Future, 1998). 
Collaboration is also fundamental to recent reforms of NHS R&D funding (Supporting R&D in 
the NHS 1994; Culyer, 1996).  
 
These factors are important to the design of a monitoring system. Indicators form part of the 
incentive structure, rewarding or penalising particular activity. The choice of indicator will, 
therefore, affect the likelihood of collaboration occurring. It is possible to design a monitoring 
system with indicators that directly measure (and therefore reward) collaboration. This is 
already common among funding bodies, which make ex ante evidence of collaboration a 
prerequisite to some types of funding (Landry and Armara, 1998). Indicators should also be 
consistent with the outputs of each type of research if they to be consistent with 
collaboration.  
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In general, differences between different types of R&D affect what will be measured. The 
different types of R&D generate different outputs and outcomes, and may therefore perform 
differently on the same measures.  As will be discussed in Chapter 6, recognising this is the 
case is central to designing a valid monitoring system. 
 
Performance on bibliometric indicators, for example, will be affected by differences in norms 
about whether, where and what to publish, meaning that variation in publications cannot be 
interpreted as necessarily indicating variation in payback. Social scientists, for example, tend 
to have fewer publications, containing larger 'chunks' of research, than natural scientists. 
Variations in Journal Impact Factors (JIF) between fields may similarly reflect differences in 
the outlets used by different types of research, or differences in the size of a field. These 
factors mean that bibliometric indicators of payback can be used to compare different fields 
or types of research only after confounding factors have been controlled.  
 
Reservations about the use of bibliometric indicators are particularly important in the context 
of health-related research, since relevant R&D occurs across a number of different subjects 
and in all three broad types of R&D.  
 
Moreover, important differences between the incentives governing basic as opposed to 
applied researchers mean that bibliometric indicators should not be used as the sole basis 
for comparing all types of research (Black, 1997; Dasgupta and David, 1994). Employing 
publications as an indicator is consistent with desirable behaviour by basic scientists, since 
this is a measure of whether knowledge is placed in the public domain. Publications are, 
however, inconsistent with the incentive structure governing many clinicians, since they are 
often not rewarded for publications. Unless they have a university contract, their employment 
is generally not conditioned on their R&D activities (Fears and Poste, 1998). Hospital 
medical consultants, for example, are contracted to undertake patient services, not to 
undertake R&D (Elderidge and South, 1998; HSMU, 1999).  
 
Whereas publications reward making knowledge public, patents effectively ‘privatise’ 
knowledge. They therefore allow innovators to appropriate returns on their investment in 
R&D, perhaps giving them an incentive to make that investment. Patents may, therefore, 
promote desirable behaviour in some types of researcher, particular those engaged in 
experimental development. They are not, however, desirable in all contexts since many 
types of research do not lead to patentable results, nor is it clear that privatisation of applied 
knowledge promotes efficiency in health care.  
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Table 2 summarises the measures of payback, including bibliometric measures, that are 
suited to different types of research. Expert review is suitable for all types of research. User 
review is feasible only for applied and experimental R&D since, by definition, the users of 
basic research are not likely to be known.  Questionnaires to researchers are relevant to all 
but may need to be adapted to the particular type of research in question.  Bibliometric 
measures are particularly relevant for basic research and some types of applied.  Economic 
appraisal is unlikely to be feasible for monitoring basic research, given the uncertainty about 
the eventual uses of the research and the long time lags involved. Moreover, the data 
required for meaningful economic appraisal mean that it can be used only for detailed 
examination of a few studies. Case studies, involving detailed investigation of the outcomes 
and outputs of particular R&D projects may be useful for all types of R&D.  
 
Social care research 
For some health research funding agencies there may be a need to consider applied 
research that is not concerned with health per se, for example research on aspects of 
education or social care. Do these raise special problems?  Taking the example of research 
on social care, it would appear in principle that they do not.  Reviews of social care research 
have indicated that it has had impact on policy and practice (Kogan and Henkel, 1983; DH, 
1994).  It has also proved possible to apply the HERG general approach used to value DH 
research to some social care projects and programmes (Henkel, 1994; Youll, 1997).   
 
Inevitably some of the categories of health benefits and detailed ways of assessing them will 
be different for social care research than for health.  Furthermore, some items suggested in 
Chapter 6 may not be relevant. The variations in publication patterns discussed above are 
also relevant to social care research where books can sometimes be the major publications 
outlet. Nevertheless at this stage it seems likely that the broad approach proposed in 
Chapter 6 could apply to social care research. Applied social care research may have 
greater similarities with applied health research than applied health research has with basic 
biomedical science. related to health.  
 
Commissioned versus responsive R&D 
A distinction may also be drawn between commissioned and responsive R&D. The 
distinction is relevant to the design of a monitoring system and choice of indicators.  For 
responsive R&D, resulting from open applications to a funding body, funding is given for the 
investigation of topics chosen by researchers. Commissioned research may take the form of 
a call by the funding body for research ideas on a particular topic, for example the interface 
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between primary and secondary care or issues relating to childhood asthma. Alternatively, 
commissioned research may be even more prescriptive, defining the research question and 
the method.  
 
Unlike responsive research, commissioned research prescribes the type of knowledge that 
should be generated by the R&D. As pointed out by Thomas (1985), government 
commissioned research has built into it some of the minimum conditions for outcomes to be 
generated. The fact that a particular area is selected for commissioned research suggests 
that the funder has already identified that a contribution to knowledge in this area will be 
valuable. In other words, that this is an area where reducing uncertainty by increasing 
information might generate payback (Claxton, 1998). In this case, the funder requires a 
monitoring instrument that tracks whether the anticipated payback is achieved. The 
prescriptive nature of commissioned research means that it should, therefore, generate its 
own monitoring criteria, in terms of the contribution made to the area of knowledge defined 
by the funder. In the case of responsive research, by contrast, the expected contribution to 
knowledge is defined by the researchers themselves. Sometimes it is explicitly part of a 
funding application.  
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Conclusions 
This chapter has described various different types of health R&D. The different types of 
research generate different types of outcomes and are likely to perform differently on the 
same measures of payback, for reasons not necessarily related to the value of the research. 
Funders’ objectives often mean that they are interested in having a balanced R&D portfolio, 
incorporating a range of different types of R&D. A routine monitoring system must therefore 
be capable of recognising and rewarding a range of different types of R&D. The system 
outlined in Chapter 6 has the potential to achieve this. 
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CHAPTER 5 : WHICH UNITS OF RESEARCH? 
 
Introduction: what are we concerned about? 
In developing a system for monitoring the R&D activity of a funding agency, there is a need 
to be clear first, about the basic units of R&D on which data will be gathered, and secondly, 
the way these may be combined to inform judgements about the relative performance of 
different parts of the agency’s portfolio. These two issues are inter-related.  
 
This chapter outlines the basic types of funding: projects, centres and individuals. It also 
proposes how data can be collected on outcomes for each of these, in the light of previous 
attempts to do so.  
 
The main streams of research and the levels within them 
In describing the levels at which monitoring could be applied, the diverse use of the term 
'programme' has to be addressed.  The term is often adopted to describe a collection of 
projects based on a common theme, for exampleeg, mental health, but funded at a range of 
institutions. In such a situation, there may be an expectation that interaction and synergy at 
research and dissemination stages should enhance the outcomes and, to differing degrees, 
resources are often employed to encourage this.  (The label programme is sometimes also 
used to describe the entire collection of projects funded in the responsive mode, but here 
there is no project interaction or common themes).  Another frequentmain use of the term is 
to describe ‘block’ funding to an institution, centre or research unit, or to describe long term 
funding to an individual, where the broad subject matter is agreed between the funding 
agency and the recipients, but the latter have freedom over details relating to the use of the 
funds.as to how the money should be used in detail.   
 
To provide an overall framework, whilst avoiding confusion over the use of the term 
programme, we identify three main streams or modes of research funding. One main funding 
stream is usually for projects administratively grouped into programmes, including a 
responsive mode ‘programme’. The second main stream is funding for institutions/centres: 
this stream includes, in the case of DH/NHS, the ‘Budget One’ funding for hospital trusts but 
also includes funding to some university based research units or centres. The third main 
funding stream is to individual researchers as training or career development awards.  An 
agency could have a range of such schemes, for example for PhD fellows, for post-doctoral 
fellows etc. These three streams are shown in Figure 1 and it is probable that the regular 
data-gathering for a monitoring system would operate at the basic level of each stream.  This 
is how the analysis in the next section is organised.   
  30
 
Applying indicators to the three streams 
It is helpful to consider separately the three streams of R&D activity identified above, and 
how the indicators discussed in Chapter 2 can be applied at the various levels within them. 
 
Stream 1: Projects in themed programmes or responsive mode 
The individual project is the basic level for funding in the responsive mode and for many 
programmes.  Before considering how this level can be viewed as the most appropriate data 
collection level, it has to be noted that this approach has been subject to criticism on the 
grounds that it commits the ‘project fallacy’.  This fallacy, it is claimed, is to assume that 
individual projects make substantivemuch impact as opposed to possibly playing a 
contributive role.  Nevertheless, most previous analysis of of thethe payback from 
Department of Health research analysis conducted by HERG has been at the level of 
individual projects, suggesting that payback categories and indicators are applicable at this 
level - especially in the two phases of work for the Department of Health (Buxton and 
Hanney, 1994, and 1997; Ferguson et al, 1998).  Most of the payback categories and 
indicators have therefore been shown to be applicable at this level in at least some cases. In 
addition, HERG's work for North Thames, and that conducted in other regions has also 
concentrated on project funding (see, for example, Ferguson et al, 1998).  Similarly, a 
systematic assessments of outcomes of the Quebec Health Technology Assessment (HTA) 
programme was undertaken at the project level (Jacob and McGregor, 1997).   This 
assessment is of key importance because it found evidence that 18 out of the 21 HTAs it 
assessed had an impacted on policy.  This is a much higher proportion than other 
researchers usually claim for policy research, and indicates both that HTA might be a 
particularly fruitful area for examining outcomes and that assessments can operate 
successfully at the project level. 
 
 
Previous workHERG's work for the North Thames regional office of the NHS Executive 
showed that where a programme consists of an organised series of projects on one theme, 
for example mental health, that are conducted in a range of institutions, the data collection 
could be at project level, although it could be presented in an aggregate form at programme 
level.  This work showed that aAny extra benefits that may arise, in terms of quality of 
research and its impact, as a result of projects being part of programmes, should be capable 
of being gathered in the project level data collection.  
  31
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But whilst much of the data collection is likely to take place at a project level, expert/user 
review can be used at programme level.  The results of ESRC's examination of the role of 
user panels for assessing the impacts of its programmes on users could be important here.  
It is possible however, as shown in HERG's analysis of North Thames Mental Health 
Programme, for the projects to have impacts but the programme not to be well known to 
some of the most obvious potential users. 
 
Previous experience of surveying users of Department of Health funded projects has had 
only had limited success.  Although some studies have involved asking departmental 
personnel about their use of research (see, for example, Gordon and Meadows, 1981) it 
seemed to be at a more general level than in relation to specific projects. Richardson et al 
(1990) suggested the most obvious of the limited strategies available was toa survey users, 
researchers or research managers.  Their study advocated developing the pre-existing ex 
post assessment forms which asked the customer divisions about possible benefits accruing 
from research and whether the research has been used in any of the following categories: 
legislative changes; administrative changes in advice or guidance; practice action; 
confirming existing policy or practice action; further research; or active dissemination.  They 
advised the DH on the need for considerable methodological developments and the 
incorporation of qualitative approaches in any adoption of surveys of use.  We understand, 
however, that these assessment forms are no longer used by the department (Buxton and 
Hanney, 1994).   
 
OneA problem with adopting user surveys at the project level is that users, even if they are 
aware of particular findings, might not link them to specific projects from a funding agency.  
One way round this is to provide users with a list of specific projects and ask them if they 
know about, and have used the findings from, the specific projects.  This approach has been 
adopted in previous case studies (Buxton et al, 1999) with (Bryan, 1997) testing alternative 
approaches.  The dangers of asking users about named projects was highlighted by 
Drummond et al (1996) who reported that some practitioners claimed to have read, and even 
been influenced by, fictitious economic evaluations included in a survey. 
 
Stream 2: Institutions/centres 
The institutional stream is likely to involve the greatest difficulty in relation to multiple funding 
both from different streams of any specific agency and between different agencies. Funding 
from one agency at the institutional level can be used in various ways including: for general 
research infrastructure; for individual project level work to be conducted; to act as core 
funding that can be used in a leverage way to attract further funding; and for enabling 
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activities to be funded that increase the likelihood of payback accruing.  Questions arise as 
to how data should be gathered for an institution.  Should it includebe only those activities 
directly funded by the relevant agency or should it encompass other activitiesgo more widely 
when the funding is explicitly seen as having a leverage/enabling role?  Overlapping with 
this is the issue of whether the assessment of benefits from funding in an institution/centre 
stream should operate at project level or solely at the institutional level.  When these two 
issues (ie. all research at the institution v only research funded by the agency’s institutional 
funding stream; and project level v institutional level) are combined a number of options 
arise: 
 
1) The institution would report at an aggregate level (or at least in a form not related to 
specific projects) on the paybacks from all the research undertaken at the institution 
whatever the funding source.  This would be similar to some existing practices but would 
include outcomes as well as outputs.  Information would probably be gathered from 
individual researchers (who would be asked to report on the relevant outputs/outcomes 
from their work) and not on a project by project basis.  There is a danger of double-
counting both within, and between, institutions where projects are undertaken on a 
collaborative basis but where the projects on which the reporting of payback is based are 
not disclosed. 
 
2) Institutions/centres would report on the payback arising specifically from the institutional 
stream of funding supplied by the funding agency. This could be at an aggregate level or 
project by project, given that the data would probably be gathered on a project specific 
basis for those projects using institutional funding.  
 
3) Information on payback from any project or individual award being conducted at the 
centre would be gathered, and reported on, at the project/individual researcher 
development award holder level.  There would clearly be considerable overlap with 
information  being supplied about the other two streams (ie. projects and individual 
researcher development awards).?   
Institutions and Centres increasingly have experience not only of traditional periodic expert 
review but also of producing annual reports.  There has, however, long been disagreement 
about the dimensions that should be addressed in peer reviewmost appropriate criteria to 
include, with Henkel and Kogan (1981) describing the debate over whether it should go 
beyond scientific quality and also examine policy relevance.  More recently there have been 
moves to include a wider range of criteria in reviews of health research centres in the UK 
(DH, 1992) and in the Netherlands (Spaapen and Sylvian, 1994). 
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A pThe previous payback analysis carried out for an NHS region examined two centres.  An 
attempt was made to look at some individual projects or main themes of work as well as at 
each centre as a whole.  However, for reporting purposes it was felt most appropriate to use 
the aggregate level (i.e. each centre) and here the full range of payback categories was 
applied (Buxton et al, 1999; Hanney et al, forthcoming). 
 
Stream 3: Researcher development awards 
This form of funding can cover a range of circumstances, but in all cases the routine data 
collection would be from individual recipients of awards. Many funders have PhD fellowships 
schemes, but the MRC and other funders also have a range of post-doctoral fellowships.  
The aAnalysis for the North Thames region showed that whilst research training as indicated 
by PhDs would be the single most important aspect of payback to assess at this level, the 
full range of payback categories and indicators could also be appropriate.  This is because 
some projects being undertaken by PhD Fellows can lead not only to publications but can 
have an impact on policy and practice.   
 
A pilot evaluation of MRC research training schemes included issues such as the quality of 
training, and most importantly the pattern of employment and the extent to which recipients 
were contributing to, and leading, research and 'the extent to which MRC training and 
development awards had contributed positively to the career development of recipients' 
(MRC, 1996).  In addition to indicators based on employment, and on continued involvement 
in research, some of the indicators used and recommended for future use involved 
assessing the publications record of former fellows.  There were no indicators used or 
proposed that related to the impact of the research undertaken.  It is also important to note 
that it was proposed that exercises of this kind should concentrate on individuals who had 
completed awards at least six years prior to the assessment.  
 
 
Conclusions 
This report is primarily concerned with showing how the benefits from a funding agency's 
research could be presented. We are proposing that payback be assessed by separately 
considering three main streams and various sub-levels within them, but this chapter has 
outlined a number of complications that arise when trying to do so.  In the US the NIH is 
proposing that its GPRA report should be at full agency level.  An advantage of operating at 
agency level is that it allows a portfolio approach to be used to explore the extent to which 
the programme as a whole shows an appropriate balance of  risk, and of time-scales etc. 
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Nevertheless, data on various streams would be needed if the monitoring is to be used for 
the management purposes discussed earlier.
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CHAPTER 6 : PROPOSED COMPREHENSIVE ROUTINE MONITORING SYSTEM 
 
The purpose of this chapter is to describe a system that could be used to monitor R&D 
routinely. The system is designed specifically for use by the DH/NHS to monitor R&D they 
have funded, but is also relevant to other funders. It is designed to provide information useful 
both for justifying the DH’s investment in R&D and for managing the department’s R&D 
budget. The information necessary for the latter comprises information that will inform 
resource allocation decisions by refining estimations of expected payback from different 
uses of funds, as well as information providing ex post insight into the outcomes of R&D. 
Achieving the dual purposes of justification and of management affects the information that 
needs to be collected. A system designed solely to demonstrate the overall use of R&D 
funds would require less detail on individual projects, at less frequent intervals. 
 
This chapter draws together insights from previous chapters about the prerequisites for a 
valid monitoring system. The central insight is that the system’s components must be 
relevant to the funder’s objectives. The objectives should inform decisions about which of 
the dimensions of value outlined in Chapter 2  must be measured by the system. The DH is 
concerned with payback across all dimensions, particularly health-related benefits. The 
system must therefore be comprehensive in the sense that it is capable of measuring all 
relevant dimensions. The DH and NHS fund both basic and applied R&D, so the system 
must also be able to accommodate the differences between these types of R&D, as outlined 
in Chapter 4. The DH funds R&D in three main streams, projects, centres and individuals, so 
the system must be sufficiently flexible to measure outcomes from each of these streams 
and at appropriate levels within them, as outlined in Chapter 5. Any system must also be 
operationally feasible, and meet the criteria outlined at the end of Chapter 3. It must be 
relevant to objectives, be decision-relevant, be capable of getting accurate information, 
minimise unintended consequences, and have acceptable net costs.  
 
Taking these factors into account, we again recommend the use of a multi-dimensional 
approach. The arguments rehearsed in Chapters 2-5 suggest that no single indicator will 
give adequate information about all dimensions of payback from all types of R&D. The 
system we propose for projects, centres and individuals is based on three sources of 
information. The first source is information gained from direct monitoring of researchers and 
their organisations. Some important categories of payback would not be adequately 
measured by using only information from this source, so we recommend that this be 
supplemented by a second source, external databases, and a third source incorporating 
peer review, user surveys, analysis of policy documents and case studies of selected 
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projects and individuals. Without the third source, a routine monitoring system will not deliver 
sufficient information on health benefits to provide information useful to the DH. 
 
The first and second sections of this chapter summarises the proposed system. The first 
describes the methods we recommend be used to collect information. The second section 
sets out the types of payback that we recommend be the focus of the system, and the 
outcomes and outputs we recommend be used as measures. The third section outlines the 
key issues that must be resolved before the proposed system can be operationalised, and 
uses the criteria set out in Chapter 3. 
 
Sources of information for a routine monitoring system  
The instruments available for measuring the payback from R&D were described in Chapter 2 
. We propose using information derived from a number of these sources. We propose a 
system with three broad components: first, information that is collected directly from those 
funded in all three streams of R&D activity; secondly, information derived from external 
databases; and thirdly, supplementary information collected from a sample of projects, 
centres, or people. 
 
1. Information collected directly from those funded, for all R&D activity.  We propose that a 
set of information be collected for each project, each research centre and institution, and 
each researcher holding a personal award. At least for projects and researchers this 
information can be obtained using questionnaires (possibly administered electronically). A 
postal questionnaire approach was piloted in the North Thames NHS Region by HERG, 
Brunel University, and showed that this is feasible, although without clear sanctions there 
was an incomplete response. 
 
Further work is necessary to determine how often the information should be collected and 
analysed. The length of the optimal reporting period depends on the costs involved in 
making and analysing reports, the benefits to the DH of having interim information, and the 
length of time before outputs and outcomes accrue. This period might be longer for centres 
than projects, if they receive infrastructure funding for extended periods. 
If information is to be collected electronically, it may be feasible to administer this as a 
continuously updated electronic database. In other words, researchers, organisations or 
award holders may supply information, as and when it is availabe, directly onto the 
database.  (An approach similar to this is used by ESRC's REGARD system.)  Researchers 
would need only to add material to the database if they had something positive to say, in 
other words it would not have 'no' boxes. 
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This part of the proposed system must be consistent with other reporting requirements and 
infrastructure. Information collection should be co-ordinated and perhaps combined with the 
interim and final reports currently required of DH funded projects. As will be suggested in 
Chapter 7, additional work should be undertaken to investigate the pros and cons of 
standardising final reports across all DH projects.  
 
Similarly, there are existing systems for reviewing organisations. There is an annual 
reporting period for recipients of NHS R&D programme Budget One funding; there are 
quinquennial reviews for a number of centres funded by the Department of Health; and 
research institutions are currently required to file quarterly reports on their R&D projects to 
the National Research Register. It is important that any new system be consistent with fixed 
parts of the existing system.  Ensuring that a new system is compatible with existing practice 
is one way of reducing costs to researchers,  thereby increasing the likelihood of 
compliance.  
 
2. External databases.  We recommend that external databases be used to supplement 
information collected directly. The citation indices and the Wellcome Research Outputs 
Database include bibliometric information about publications and some information about 
funders. This information should initially be used to validate responses obtained directly from 
individuals. It has the advantages of being in standardised format and reducing the 
administrative burden on researchers but, as discussed in Chapter 2, the disadvantage of 
being incomplete. We need empirically to establish how much information is lost by using a 
database.  
 
3. Supplementary information, in the form of user surveys, review by experts and peers, 
case studies and analysis of sources used in policy documents. This last involves tracking 
the inputs to policy documents, such as guidelines. It is not currently routinely
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undertaken. As will be discussed in the next section, this information should be collected on 
a rolling sample of projects, centres and individuals. It is, however, vitally important that it be 
collected if we are to gain information on health and economic benefits, and if we are to be 
able to verified the direct returns made by researchers and organisations.  
 
Outputs and outcomes to be measured  
The sources of information sketched above can be used to measure payback in the 
dimensions of primary interest to the DH. As shown in Table 3, these sources can be used 
to measure a range of outputs and outcomes, which collectively give information relevant to 
payback in terms of contribution to knowledge, research capacity, influence on policy, health 
benefits and economic benefits. The outputs and outcomes we recommend that information 
be collected upon comprise: 
• the number of and nature of publications; 
• the number of and nature of publications in the so-called ‘grey literature’, defined 
as material not published in formal outlets, in other words publications without an 
ISBN or ISSN;  
• the number of and nature of patents; 
• the contributions R&D makes to future R&D; 
• development of research capacity, including researchers skills, higher degrees, 
and equipment; 
• for personal funding, information about career development; 
• whether the R&D has informed policy decisions or documents, such as guidelines; 
• health benefits of the various types described in Chapter 2 ; 
• economic benefits. 
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Table 3  Outputs and outcomes by measurement vehicle 
 
 We recommend collecting this information 
 Important to collect, but difficult 
 Not recommended, but preferred method for this category of payback 
? Possible to use this method as a source for this information 
D Possible, but difficult to use this method as a source for this 
information 
 
 Self 
Reporting 
(questionnaires 
or  annual 
reports) 
External 
Datasets 
User survey Policy 
document 
source 
analysis 
Peer/expert 
review 
Case studies 
Publications  
 
? [1] ? [2]   ? ? 
Grey literature 
   
? [3]     ? 
Patents 
 
? ?   ?  ? 
Contributions to 
further research 
?  ? [4] ? [5]  ? [6] ? 
Higher degrees 
 
? [7]     ? 
Research capacity [8] ?     ?  [9] ? 
Utilisation of existing 
research 
D    ? ? 
NHS Staff 
development 
?     ? 
Dissemination 
activities 
?  ?   ? 
Impact on policy 
documents/guidelines 
?  ? ?  ? 
Other political benefits D  ?   ? 
Health benefits 
 
?  ? [10]  ? [11] ? 
Economic benefits D    D  [12] D 
[1] number of publications and, for each publication, data on the journal, type of publication (whether an article, an 
editorial, and so on), and number of collaborating authors.  
[2] relevant information contained in the Science and Social Science Citation Indices, Medline, and Research 
Outputs Database.  
[3] number and type of output. 
[4] citations analysis 
[5] as part of a wider survey of users 
[6] review by research peers 
[7] number and nature of higher degrees 
[8] includes, for example, the development of researchers’ skills and additional equipment 
[9] review by research peers 
[10] survey of users in the health-services  
[11] review by experts in the health services, by research peers, and by representatives of patients. 
[12] review by economists and health service professionals.  
  41
We suggest that information on all dimensions except economic benefits be collected 
routinely, directly from researchers and organisations.  We have omitted several categories 
of payback since, although involving useful outputs or outcomes, they are either ambiguous 
or difficult to measure. We do not recommended that information on the following be 
routinely collected, but Table 3 indicates the source recommended if they are deemed 
important:  
• utilisation of existing R&D; 
• development of NHS staff educational benefits from participation in R&D; 
• dissemination activities; 
• other political benefits. 
 
As noted in Chapters 2 and 3, there are a number of dimensions of payback on which 
researchers and their organisations are unlikely to have full information. Moreover, the 
information supplied by those directly involved in R&D may not be reliable. The regular direct 
returns should therefore routinely be supplemented with the following information, 
undertaken on a sample of projects or organisations:  
• user surveys should be undertaken routinely, using relevant users, on a sample of 
projects or institutions, to assess the contribution to policy, to future R&D capacity and 
possibly to health. Users provide a vitally important perspective on the value of 
outcomes. Their views can be obtained by surveys or by inviting representatives to join 
review panels; 
• analysis of the sources used in particular types of policy documents such as guidelines 
(perhaps those endorsed by NICE), should be routinely undertaken to determine which 
R&D projects or institutions have influenced policy (Grant 1999); 
• expert review should be undertaken routinely, on a sample of projects or institutions, to 
assess the following: 
• contributions to future R&D (where the experts comprise research peers); 
• development of research capacity (using research peers); 
• health benefits (using health professionals, managers, social scientists, and 
patient representatives); 
• case studies should be used if economic benefits are to be monitored. Case studies can 
also be employed, to supplement the above by providing additional, in depth, information 
on any of the outputs or outcomes. The importance of health benefits to the DH suggests 
that case studies, the best method for identifying health benefits, should be an integral 
part of the routine system. 
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As will be discussed below, these supplementary methods are not only a vital source of 
primary information, but they also provide a method for verifying information collected 
directly from researchers and their organisations.  
 
It is feasible to collect this supplementary information, using user surveys, expert review, 
source analysis and case studies, only on a subset of projects or organisations. The choice 
of a sample will be constrained by practical considerations discussed in Chapters 2 and 3. 
First, the size of the sample will be constrained by cost, meaning that the value of additional 
information generated by these techniques must be assessed against its cost. Secondly, the 
methods are not universally applicable. The users of R&D, for example, are often not able to 
attribute particular health gains and R&D outputs to particular projects, suggesting that user 
consultation will not be able to be applied to all areas. Chapter 7 suggests that additional 
work be undertaken to determine the appropriate method for choosing which projects, 
programmes or individuals are subject to what type of additional analysis.  
 
The structure of the system, in terms of the dimensions measured and the measures used 
can be applied to centres as well as to individual projects. However, we have not resolved 
the issue of whether a centre needs to relate all of its outputs to individual projects, or 
whether some can be presented as an aggregate for the institution. In principle, the same 
categories can also be applied to awards to individuals. However, there may be an argument 
for restricting the focus for individual awards to the first six categories of Table 3.  
 
Key issues  
The system must be evaluated against the criteria set out in Chapter 3. It must maximise 
relevance to objectives, decision relevance and accuracy, and minimise unintended 
consequences and net costs. 
 
Relevance to objectives 
The system sketched above has been designed to be relevant to the DH’s objectives of 
funding R&D which generates value in a number of different dimensions. It has also been 
designed to accommodate the differences outlined in Chapter 4, between basic science and 
applied R&D, between commissioned and responsive R&D, and to be appropriate for R&D 
related to social care.  
Decision relevant 
Decision relevance requires that the right types of information be collected at timely 
intervals, and presented in a form consistent with decision making processes.  
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Whether the system is decision relevant depends in part on solving the problem of financial 
attribution. The DH may wish to identify the separate and additional impact its funding makes 
to payback from R&D. In this case it is necessary to find a means of apportioning funding to 
outputs and outcomes. As shown in Table 4, in this case information will be needed about 
the different funding streams contributing to each publication, each grey output, each higher 
degree and each patent. This information should (or could) be supplemented by an estimate 
of the proportion of each output able to be attributed to each funding source. This is an 
ambitious requirement, raising conceptual and practical problems. It is likely to be difficult for 
researchers to attribute proportions of each output to different sources, and it may be 
resented by researchers, undermining the criteria of having a system that encourages 
compliance. It may, however, be a necessary task.  It could be made more palatable if it 
were required by all funders, and could in the long-term perhaps become information that 
was routinely noted in publications. We propose the feasibility and acceptability needs to be 
tested. 
 
Decision relevance also requires that information be able to be analysed and presented in a 
manner consistent with funders’ decision making processes. It is difficult to achieve this 
simultaneously with the first criterion, which requires a degree of comprehensiveness and 
therefore entails the collection of information from a number of disparate R&D activities 
using a variety of different measures. The system that is sketched in this chapter will 
generate a huge quantity of data, on a number of different dimensions. This in turn leads to 
significant problems when analysing and then presenting information useful for managing 
the R&D budget. The first problem is that, within each dimension of value, the outputs 
generated by different types of R&D activity may not be comparable. For example, as was 
discussed in Chapter 4, publication patterns vary between disciplines and different 
publications might have different value.  The second problem arises when trying to 
aggregate the outputs and outcomes from all of the dimensions. How, for example, will 
instances of policy influence be combined with or compared against instances of health 
gain? A process,
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Table 4  Financial attribution of outputs 
 
 We recommend collecting this information 
 Important to collect, but difficult 
 Not recommended, but preferred method for this category of payback 
? Possible to use this method as a source for this information 
D Possible, but difficult to use this method as a source for this information 
 
 
 Question-
naires 
External 
Datasets 
User survey Policy 
document 
source 
analysis 
Peer/expert 
review 
Case studies 
Publications 
 
? ?     
  funding sources 
 
? D     
  % each output 
attributable to funders 
D      
Grey literature ? 
 
     
  funding sources ? 
 
     
  % each output 
attributable to funders 
D      
Higher degrees ? 
 
     
  funding sources ? 
 
     
  % each output 
attributable to funders 
?      
Patents 
 
? ?  ?   
  funding sources ? 
 
     
  % each output 
attributable to funders 
D      
 
 
 
probably subjective, will have to be designed to bring together all the disparate types of 
information collected by the system. Unless these problems can be resolved, the information 
generated by the system may not be useful for the purposes of managing the budget. 
Resolving this problem is relevant to ensuring that the final criteria of acceptable net costs, 
discussed below, is met. The costs of collecting detailed information can be justified only if is 
possible to find a means of using that information to realise the benefits of decision-
relevance.  
 
A funder such as the DH may wish to make its decisions based on potential rather than on 
realised payback. On the one hand, it can be argued that if the DH delivers R&D projects, it 
is not necessarily its responsibility to ensure that results are implemented. On the other 
hand, it can also be argued that no distinction should be drawn between R&D and 
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implementation: that failure to realise benefits may be a consequence of the way the R&D 
was designed or the results disseminated. The DH needs to consider whether research has 
been implemented if it is to truly judge the value of its investment.  
 
Accuracy 
Any system must aim to generate information that is sufficiently accurate for its intended 
use. Information collected directly from organisations might be inaccurate because of errors 
or because of deliberate manipulation. Errors can be minimised by appropriate system 
design, by resourcing those making returns so that they have time to collect accurate data, 
and by monitoring returns.  
 
We recommend that external databases be used as a means of monitoring information 
provided by researchers or their organisations. This can be achieved by, for example, 
comparing reported publications with those appearing in a database. In addition, those 
undertaking periodic reviews can be asked to comment on claims made in questionnaires; 
and ad hoc case studies can be carried out to amplify and verify particular reports or on 
particular issues. The use of an electronic data-base, available for scrutiny by other 
researchers, might also help maintain veracity. Furthermore, internal validations built into 
such systems 'help prevent projects from entering most out-of-range data, thereby improving 
data accuracy over traditional survey methods' (NSF, 1998). 
 
Consistency between the reporting requirements of different funders may promote accuracy. 
If we are to move to a system of annual reporting with multiple funders, it is advantageous if 
all funders use the same format. This would limit the possibility of researchers manipulating 
the system by multiple reporting of single outputs, as well as minimising their administrative 
burden. 
  
R&D outputs and outcomes accrue gradually over time. This means that outputs and 
outcomes relating to a single project, programme or person are likely to be reported over 
several years. It is important that the system is capable of eliminating duplicates, and that 
returns are compatible. Direct entry to a database that the researcher can review will help to 
avoid duplicates. But we believe that data will also need to be ‘cleaned’.  
In general, the problem of attribution has to be resolved if a system is to generate accurate 
information. As previously discussed, the attribution of impact on policy or practice to 
specific projects by researchers is difficult.  The complexity of this is increased the longer the 
time lags involved, since this increases the likelihood that any outcome will be the result of a 
number of research projects involving researchers possibly funded from a number of 
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different agencies.  It may be hard even for expert reviewers to attribute impact to particular 
projects or institutions.  Moreover, where individual projects do make an impact, the time 
lags are sometimes so great that it may be difficult to ensure that they are picked up in a 
routine system.  
 
Whether the process is acceptable to and is taken seriously by researchers depends on 
whether proper checks and incentives have been built in. There may be an adverse reaction 
and non-compliance from researchers and institutions, if they object to the amount of 
information requested. The objection might relate to the costs involved in providing the 
information or to the principle of reporting in an area where they have previously been 
relatively autonomous. We anticipate particular problems in obtaining information enabling 
funding to be meaningfully apportioned to each output. Whilst previous work has not fund 
evidence of a systematic tendancy to overstate impacts, if researchers and their 
organisations believe that funding relates to the information they give, they have an incentive 
to exaggerate the impact of their work.  
 
Minimise unintended consequences 
Performance measurement may give rise to unintended consequences if the measures 
include ‘perverse incentives’ and behaviour changes in response to those incentives. The 
previous section outlined some perverse incentives with respect to information disclosure. 
There may also be perverse incentives with respect to R&D activities, or dissemination of 
results. Measuring, and rewarding, only R&D that generated publications in high JIF 
journals, for example, may create an incentive to shift R&D activity from specialised clinical 
applications to research likely to lead to publications in those journals. This may, from the 
perspective of the DH, be an undesirable, unintended consequence.  
 
Acceptable net costs 
The direct costs of implementing indicators are borne by the monitoring authority and by the 
researchers and their organisations themselves. The costs to the monitoring authority maybe 
considerable: Project Hindsight took more than forty person-years (Sherwin and Isenson, 
1966). Data collection is necessarily costly, posing problems for public agencies in a policy 
environment emphasising the importance of reducing organisational costs. 
 
The direct costs to researchers and their organisations may also be considerable. The 
growing administrative burden on UK researchers has been noted (Millar, 1998). Different 
indicators have different costs, and they are distributed differently between researchers and 
auditors. Bibliometric indicators based on public datasets do not necessarily involve any 
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costs to researchers (except perhaps in checking the accuracy of the dataset). Case studies, 
surveys and appraisals do involve researchers, and depending on coverage are likely to be 
more costly for the monitoring body. The total costs of the system and their distribution 
between different participants are therefore both important. Measures which require high 
administrative input from researchers are unlikely to succeed. 
 
The costs include not only the direct costs of  carrying out performance measurement. There 
may also be an indirect cost if researchers become disaffected by onerous or apparently 
‘pointless’ reporting requirements. It may, of course, be impossible to completely avoid 
disaffection, since one of the aims of a system of performance measurement is to impose a 
degree of accountability. It must nonetheless be realised that this may affect research output 
and, therefore, payback. The gains likely to accrue from better monitoring of payback must 
always be compared with these losses, as well as the direct costs incurred by the monitoring 
body.  
 
Overall administrative burden on researchers can be minimised by making the system for 
measuring value consistent with other reporting requirements, such as final reports.  
 
This criteria requires that costs be acceptable relative to benefits. In practice, gross costs 
are also important, given the priority given to minimising organisational costs. It is also 
important that these costs be compared to the benefits generated by the system: the system 
itself be subject to payback analysis. Areas of likely payback include: focusing decisions, 
contribution to knowledge of paybacks, defend funding. 
 
  48
Conclusions 
This chapter has sketched a system that can be developed for use as a way of routinely 
monitoring DH R&D.  We have assessed the proposals against key criteria, recognising that 
a balance must be struck between comprehensiveness, accuracy, incentives and costs.  
The level of detail proposed is necessary if the DH wishes to use the system for managing 
R&D as well as for justifying the overall budget. If the latter were the sole objective, the 
system would need less detail and would also be less costly. The overall value of this 
system must be empirically tested, in relation to its intended uses.  
 
If this system is to achieve DH’s managerial objectives,  it is essential that a method for 
financial attribution be determined. A prerequisite to this may be co-ordination with other 
major funders, notably the Medical Research Council and Wellcome Trust, at least to ensure 
that the concept of financial attribution is legitimate. The need for financial attribution and the 
feasibility of achieving it are both identified in the next chapter as areas requiring additional 
research.  
 
The system we propose is incomplete, in that a number of elements need further refinement 
or specification.  Whether the system infact meets our criteria will depend on finding and 
implementing an appropriate design. Several of the components requiring further analysis 
have been identified and are discussed in the next chapter (Chapter 7).  
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CHAPTER 7 :   RESEARCH AND MONITORING 
 
This report is primarily concerned with making substantive proposals for a routine monitoring 
system, basing the proposals on existing research and previous studies.  It will be clear, 
however, that on some issues we feel that there is not sufficiently clear evidence to give us 
full confidence in the feasibility of our proposals. We therefore identify in this chapter 
feasibility testing that needs to be undertaken before embarking on full implementation.  In 
the case of some items of data proposed, we have argued that until such data has been 
collected for a period, we cannot be sure how much additional value it will contribute.  Those 
issues, where we recommend monitoring of their specific value, constitute a second group of 
studies that will need to be undertaken.  The database will, in addition to providing 
information for the main purpose identified, provide a rich data-source for research on 
payback and we indicate here some of the issues that it can illuminate.  A range of further 
issues needs to be examined which may in turn lead to subsequent modification of the 
monitoring system.  Finally, we emphasise that the system is intended primarily to meet 
specific objectives and needs itself to be evaluated in use.  
 
Issues for feasibility testing 
• The feasibility of, and researcher compliance with, requests to attribute proportions of 
research outputs to separate funding agencies/streams. 
• Analysis of the feasibility of standardising final reports, both those within the DH research 
ambit and those of other funding agencies, and of developing such a standard format as 
far as possible.    
• Testing the feasibility and user-friendliness of a system of on-line recording of data on 
projects. 
• Testing the acceptability of these proposals to other major relevant UK research funders, 
and establishing whether their requirements would be met within this system. 
• Testing the implications of alternative data requirements from centres. 
 
Issues for specific evaluation once a system is implemented  
• Comparison of self reporting of all publications with external database analysis of 
publications.  What is the incremental value of the former? 
• Analysis of where best to focus those aspects of monitoring, for example the use of user 
surveys, that it is proposed are applied to a sample of cases.  
• Detailed analysis of the extent to which the database makes it possible to make 
meaningful comparisons between the impacts of different funding streams.  
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Research opportunities provided by the database   
• Analysis of the correlation between publication outputs and the various other categories 
of payback to see whether publications can be used in some way as an acceptably good 
proxy for other outcomes. There is some evidence on the relationship between 
publications and  quality (Cave et al, 1997), but no real evidence exists for the 
relationship between publications and ‘payback’. 
• Study of the correlates of research success, investigating the relationship between input, 
and research process, on the one hand and the quality of research on the other. 
• Study of whether there appears to be any unnecessary redundancy of data or key items 
missing form the system  
 
Other important related research issues 
• Can we identify and test the added value performance indicators suitable to measure 
collaboration? 
• The value of ‘network analysis’, which is not currently included in our proposals, should 
be reviewed as a possible indicator of the necessary conditions for impact, once the 
findings of a current ESRC study have been published. 
• Development of a more robust and comprehensive classification system of research 
types for bibliometric analysis.  This might replace the categorisation of journals into 
'Research Levels'. In addition it might be possible to develop a system more relevant to 
the NHS for ‘weighting’ journals, to be used instead of existing Journal Impact Factors. 
• Does research funding attract leading clinician researchers to the UK, and if so should it 
be included as an additional category of payback? 
 
Value in use 
• Study of whether the monitoring system has aided the DH in justifying expenditure on 
R&D by providing evidence of its value. 
• Study of whether the monitoring system has aided the DH in improving management of 
R&D resources, through a better understanding of differential payback from different 
types of research or modes of funding. 
• Analysis of what have been the incentive or disincentive effects of the monitoring 
system, on the various types of researcher involved.  
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Final comments 
We have indicated above that a number of specific issues of feasibility need to be addressed 
prior to trying to introduce a monitoring system.  We also stress that its value should not then 
be taken for granted but should be tested in the light of the use that is made of the system. 
 
We have previously pointed to the fact that the need for greater accountability, and for 
formal monitoring is internationally a growing requirement for the proper management of 
public resources.  However, the sort of system envisaged here goes, we believe, beyond 
what has been attempted anywhere else.  What is now needed are informed views as to 
whether all, or part, of the system proposed would appear to constitute a good investment of 
resources, in terms of both central management effort and ‘imposition ‘ of tasks on 
researchers.  If so, there may still be a question as to whether this is the right time to embark 
on such a system.   
 
The ‘Leeds Castle Workshop’ will provide a first opportunity to obtain a wide range of views 
about these important questions. The participation in this workshop is at least indicative that 
these are issues that others see as  important and warranting serious discussion.  We hope 
that this paper will provide a basis for such discussion, and subsequent development of 
ideas.  
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